Dakota Wealth Management Purchases 5,701 Shares of Boston Scientific Corporation $BSX

Key Points

• Dakota Wealth Management increased its holdings in Boston Scientific Corporation by 2.4%, now owning a total of 238,666 shares valued at approximately $25.6 million after acquiring an additional 5,701 shares.
• Several institutional investors have boosted their stakes in Boston Scientific, with Vanguard Group owning nearly $13.6 billion worth of shares after acquiring nearly 1.7 million additional shares.
• Analysts have a positive outlook on Boston Scientific, with three rating it as a Strong Buy and the consensus target price rising to $118.17 following several upgrades in July 2023.

Dakota Wealth Management raised its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 238,666 shares of the medical equipment provider's stock after acquiring an additional 5,701 shares during the quarter. Dakota Wealth Management's holdings in Boston Scientific were worth $25,635,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of BSX. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Invesco Ltd. raised its holdings in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after purchasing an additional 834,274 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Amundi raised its holdings in shares of Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after purchasing an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Boston Scientific by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider's stock worth $1,139,938,000 after acquiring an additional 460,580 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of a number of analyst reports. Robert W. Baird upped their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Raymond James Financial upped their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Finally, Needham & Company LLC restated a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a report on Friday, September 19th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $118.17.

Insider Buying and Selling at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 in the last quarter. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Up 0.3%

Shares of BSX stock opened at $98.02 on Thursday. The company has a 50 day moving average of $104.03 and a 200-day moving average of $102.03. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The firm has a market cap of $145.24 billion, a P/E ratio of 58.35, a PEG ratio of 2.35 and a beta of 0.65. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the company earned $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.